Asset profile
AV000103A (ICVAX)
Vaccine
Evidence outlook · lead readout
NCT06253533 · Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06253533: The trial is randomized, blinded, and placebo-controlled with a reasonably sized cohort, but it was designed to test safety and tolerability rather than a disease outcome, and no results have been posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.